|
|||||
|
|
The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes |
|
| Authors: | Greg Martin Frank M Brunkhorst Jonathan M Janes Konrad Reinhart David P Sundin Kassandra Garnett Richard Beale |
| Affiliation: | (1) Division of Pulmonary, Allergy, and Critical Care, Emory University, 615 Michael Street, 30322 Atlanta, Georgia, USA;(2) Department of Anesthesiology and Intensive Care, Friedrich Schiller University, Erlanger Allee 101, 07743 Jena, Germany;(3) Lilly Research Laboratories, Eli Lilly and Co, Lilly Corporate Center, 46285 Indianapolis, Indiana, USA;(4) i3 StatProbe, 1001 Winstead Drive, 27513 Cary, North Carolina, USA;(5) Intensive Care Unit, Guy's and St Thomas' Hospital, Lambeth Palace Road, SE1 7EH London, UK |
| Abstract: | IntroductionSince the launch of drotrecogin alfa activated (DrotAA), institutions and individual countries have published data on its use in clinical practice, based on audit or registry data. These studies were limited in size and geographic locale and included patients with greater disease severity and higher mortality than those in clinical trials. The purpose of this study was to compare baseline characteristics and clinical outcomes (using appropriate statistical adjustments) of patients treated or not treated with DrotAA from the international PROGRESS (Promoting Global Research Excellence in Severe Sepsis) cohort study of severe sepsis. |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |